Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
While the prolonged fight has been devastating to an already-struggling agriculture industry, there's little indication Trump is paying a political price.Traderead more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
Apple CEO Tim Cook was the commencement speaker at Tulane University Saturday. In his speech, the tech executive focused on the importance of addressing climate change and...Power Playersread more
JPMorgan health care expert Lisa Gill shared her thoughts on the drug pricing debate as well as potential stock picks in an exclusive interview with CNBC PRO's Mike Santoli.
"As we think about drug pricing, [pharmacy benefit managers] don't set the price at the end of the day," explained Gill. "The drug distributors distribute a product and, yes, when there's drug price inflation they make a fee off of the average wholesale price of the drug."
"When you think about what the pharmacy benefit management companies are trying to do, they're trying to manage and negotiate a better price."
Gill is managing director of U.S. healthcare technology at JPMorgan, where she's been a member of the health care team since 1998. Her coverage includes health care distribution, pharmacy benefit managers and drug retail. Prior to her work at JPMorgan, she was part of an audit group specializing in health care facilities at Ernst & Young.
As a part of her interview, Gill also revealed some of her favorite names in the health care space.
"We have historically have liked the PBM industry and we think that CVS is very well positioned because of that," she said. "The other one I like – I like Lab Corp – and I think Lab Corp is well positioned. It's a lab as well as on the CRO side so if we think about incremental innovation on the side of new products coming to markets, that's another name that we like."